A Phase Ia/Ib, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Patients With Lung Fibrosis or Liver Fibrosis
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs BLD-2660 (Primary)
- Indications Fibrosis; Hepatic fibrosis; Pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Blade Therapeutics
- 14 Nov 2019 Status changed from recruiting to completed according to a Blade Therapeutics media release.
- 31 Jul 2019 According to a Blade Therapeutics media release, the company expects to complete dosing in this study this quarter.
- 26 Jun 2019 Planned End Date changed from 1 May 2019 to 1 Nov 2019.